ARTICLE | Company News
Priaxon, Boehringer Ingelheim deal
January 30, 2012 8:00 AM UTC
Boehringer and Priaxon extended by one year to the end of 2012 a 2010 deal to discover and develop small molecule antagonist of mdm2 p53 binding protein homolog (MDM2) for cancer (see BioCentury, Jan...